
The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1OX01jbmg4cDl3TUlTUE1KTlZSX2tYcWVYbXpnbmMtR2l4aGVCMURRdlJtUlVFTEpldW5uNFVtbkhnS2ZBVEUybUV0eEgzeGUzSGhReGgyZlZQNzVnNGFF?oc=5" target="_blank">The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
